Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE versus QOLIANA.
HYDROCODONE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of pain.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Clinical Note
moderateHydrocodone + Torasemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide."
Clinical Note
moderateHydrocodone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid."
Clinical Note
moderateHydrocodone + Furosemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide."
Clinical Note
moderateHydrocodone + Bumetanide
Terminal elimination half-life is approximately 3.8-4.5 hours in adults; may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal (67%) as conjugated morphine and normorphine, norhydrocodone, and hydromorphone; fecal (negligible).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide."